

3726
415

PATENT

I hereby certify that on the date specified below, this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, DC 20231.

September 25, 2000
Date

Monica Steinborn
Monica Steinborn

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Jiang Yuqui et al.

Application No. : 09/551,621

Filed : April 17, 2000

For : COMPOSITIONS FOR THE TREATMENT AND DIAGNOSIS OF
BREAST CANCER AND METHODS FOR THEIR USE



Art Unit : 3736

Docket No. : 210121.470C5

Assistant Commissioner for Patents
Washington, DC 20231

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents:

In accordance with 37 C.F.R. §§ 1.56 and 1.97 through 1.98, applicants wish to make known to the Patent and Trademark Office the references set forth on the attached forms PTO-1449. This application is a continuation-in-part and relies, under 35 U.S.C. § 120, on the earlier filing date of prior application USAN 09/433,826, filed November 3, 1999; which is a continuation-in-part of 09/389,681, filed September 2, 1999; which is a continuation-in-part of 09/339,338, filed on June 23, 1999; which is a continuation-in-part of 09/285,480, filed on April 2, 1999; which is a continuation-in-part of 09/222,575, filed on December 28, 1998. The references listed on page 3 of the attached forms PTO-1449 were submitted to and/or cited by the Office in this prior application (specifically USAN 09/222,575) and, therefore, are not required to be provided in the present application. However, the references listed on pages 1-2 of the attached forms PTO-1449 were not submitted to and/or cited by the Office and are submitted herewith.

As to any reference supplied, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 C.F.R. § 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants'

duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

Please acknowledge receipt of this Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Respectfully submitted,

Seed Intellectual Property Law Group PLLC



Jane E. R. Potter

Registration No. 33,332

JEP:mls

Enclosures:

Postcard

Form PTO-1449

Cited References (24)

701 Fifth Avenue, Suite 6300
Seattle, Washington 98104-7092
Phone: (206) 622-4900
Fax: (206) 682-6031

Wpn 210121 Corixa 470e5 lds 470e5.sta.doc

FORM PTO-141 (REV. 7-80)	OCT 02 2000	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 210121.470C5	APPLICATION NO. 09/551,621
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>			APPLICANTS Jiang Yuqui et al.	
			FILING DATE April 17, 2000	GROUP ART UNIT 3736

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	5,986,170	11/16/99	Subjeck	800	2	
	AB	5,240,856	08/31/93	Goffe et al.	435	299	
	AC	5,215,926	06/01/93	Etchells, III et al.	436	501	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AD	WO 99/09155	02/25/99	WIPO				
	AE	WO 98/54963	12/10/98	WIPO				
	AF	WO 98/33915	08/06/98	WIPO				
	AG	WO 96/29430	09/26/96	WIPO				
	AH	WO 92/07243	04/30/92	WIPO				
	AI	WO 91/16116	10/31/91	WIPO				
	AJ	WO 89/06280	07/13/89	WIPO				

OTHER PRIOR ART *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	AK	Chang and Shu, "Current status of adoptive immunotherapy of cancer," <i>Critical Reviews in Oncology/Hematology</i> 22(3):213-228, April 1996.
	AL	Cheever and Chen, "Therapy with cultured T cells: principles revisited," <i>Immunological Reviews</i> , 157: 177-194, 1997.
	AM	Cheever et al., "Potential uses of interleukin 2 in cancer therapy," <i>Immunobiol</i> , 172:365-382, 1986.
	AN	Chen et al., "T-cells for tumor therapy can be obtained from antigen-loaded sponge implants," <i>Cancer Research</i> 54(4):1065-1070, February 15, 1994.

EXAMINER	DATE CONSIDERED
----------	-----------------

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicants).

FORM PTO-1449
(REV. 7-80)

OCT 02 2000

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
210121.470C5APPLICATION NO.
09/551,621

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS

Jiang Yuqui et al.

FILING DATE

April 17, 2000

GROUP ART UNIT

3736

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
BA						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						YES NO
BB						

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

BC	Cole et al., "Characterization of the functional specificity of a cloned T-cell receptor heterodimer recognizing the MART-1 melanoma antigen," <i>Cancer Research</i> , 55:748-752, February 15, 1995.
BD	Durrant L., "Cancer vaccines," <i>Anti-Cancer Drugs</i> , 8:727-733, 1997.
BE	Eshhar Z., "Tumor-specific T-bodies: toward clinical application," <i>Cancer Immunol Immunother</i> , 45:131-136, 1997.
BF	Hwu et al., "In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes," <i>Cancer Research</i> , 55:3369-3373, August 1, 1995.
BG	Porter-Jordan and Lippman, "Overview of the biologic markers of breast cancer," <i>Breast Cancer</i> 8:(1):73-100, February 1994.
BH	Wei et al., "Protection against mammary tumor growth by vaccination with full-length, modified human <i>ErbB-2</i> DNA," <i>Int. J. Cancer</i> , 81:748-754, 1999.
BI	GenBank Accession No. AA864891, February 20, 1998.
BJ	GenBank Accession No. AA398925, April 25, 1997.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449
(REV. 7-80)

OCT 02 2000

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
210121.470C5APPLICATION NO.
09/551,621**INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)

APPLICANTS

Jiang Yuqui et al.

FILING DATE

April 17, 2000

GROUP ART UNIT

3736

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	CA						
	CB						
	CC						
	CD						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	CE							
	CF							
	CG							
	CH							
	CI							
	CJ							

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	CK		Geneseq Accession Number V84525 (10 December 1998).
	CL		Stratagene 1991 product catalog, Prime-It TM Random Labeling Kit, catalog number 300387, page 66.
	CM		
	CN		

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).